Apogee Therapeutics Chief Medical Officer Sells $817,500 Worth of Shares After Monster December Rally

Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing next-generation biologic therapies for inflammatory and immunological diseases, leveraging proprietary antibody technology to address significant unmet needs in dermatology and pulmonology [6]. Recent Transaction - Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, executed an open-market sale of 10,900 shares for approximately $817,500 on December 4, 2025, marking the largest single open-market transaction by Dambkowski in the past 12 months [4]. - Dambkowski's direct holdings have decreased from 331,948 shares at the start of 2025 to 271,108 shares after this transaction, reflecting an 18.33% reduction [2]. Impact of the Transaction - The sale accounted for 3.87% of Dambkowski's direct holdings, which is significantly higher than the median per-sale impact of 1.13% over the past year, indicating a notable increase in share disposition [3]. - The transaction was part of a Rule 10b5-1 trading plan, allowing insiders to sell shares at prearranged intervals, which helps mitigate insider trading risks [7]. Clinical Developments - Apogee recently reported positive results from a clinical trial of zumilokibart (APG777) in patients with mild to moderate asthma, showing robust and durable suppression of FeNO, a biomarker of Type 2 inflammation [8]. - Anticipated milestones for 2026 include further developments for zumilokibart and a treatment for atopic dermatitis [8]. Market Context - The biotechnology sector is characterized by high-risk and high-reward dynamics, with significant investment required for research and development of medical therapies [9]. - Apogee appears to be gaining momentum as it approaches 2026, particularly following a substantial stock price increase of over 45% in December 2025 [7].